The most common adverse events were pyrexia, headache and flushing. Farletuzumab in combination with platinum and taxane increased the objective response rate of patients with relapsed ovarian ...

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...

Amgen (AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs rocatinlimab and ...

The Regional Veterinary Laboratories (RVLs) have detected Schmallenberg virus (SBV) in reports of milk drop syndrome in dairy ...

Patients with cancer cachexia and an elevated level of growth differentiation factor 15 (GDF-15) achieved significant ...

Amgen (NASDAQ:AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs ...

Let’s face it: reading medical studies from the National Bureau of Economic Research (NBER) is about as thrilling as watching ...

AEs included “reduced appetite, diarrhea, pyrexia, weariness, upper respiratory tract infection, lethargy, somnolence and bronchitis.” We also have Eisai’s Lorcaserin, which has been tested ...

of any grade in ≥7.5% of patients were nausea (18.9%), fatigue (18.9%), anemia (17.0%), abdominal pain (15.1%), constipation (13.2%), vomiting (13.2%), diarrhea (11.3%), pyrexia (9.4%), weight ...